BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Expected to Post Quarterly Sales of $2.52 Million
Wall Street brokerages expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report $2.52 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for BioCryst Pharmaceuticals’ earnings. The lowest sales estimate is $440,000.00 and the highest is $7.00 million. BioCryst Pharmaceuticals posted sales of $12.49 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 79.8%. The business is expected to report its next earnings results on Tuesday, August 6th.
On average, analysts expect that BioCryst Pharmaceuticals will report full year sales of $16.86 million for the current fiscal year, with estimates ranging from $9.79 million to $27.00 million. For the next year, analysts anticipate that the firm will post sales of $42.53 million, with estimates ranging from $20.00 million to $89.46 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.28) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.28). BioCryst Pharmaceuticals had a negative return on equity of 223.34% and a negative net margin of 472.12%. The firm had revenue of $5.89 million during the quarter, compared to analyst estimates of $2.92 million.
NASDAQ BCRX traded down $0.09 during mid-day trading on Friday, reaching $3.39. 631,162 shares of the company’s stock traded hands, compared to its average volume of 1,515,484. BioCryst Pharmaceuticals has a 1-year low of $2.80 and a 1-year high of $9.95. The firm’s fifty day simple moving average is $3.58. The company has a current ratio of 1.77, a quick ratio of 1.76 and a debt-to-equity ratio of 2.38. The stock has a market capitalization of $373.96 million, a P/E ratio of -3.46 and a beta of 2.05.
In related news, CFO Thomas R. Staab II sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $7.75, for a total value of $69,750.00. Following the sale, the chief financial officer now owns 140,426 shares of the company’s stock, valued at approximately $1,088,301.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Thomas R. Staab II sold 11,750 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $7.81, for a total value of $91,767.50. Following the completion of the sale, the insider now directly owns 137,176 shares in the company, valued at approximately $1,071,344.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 67,500 shares of company stock worth $517,223. 5.20% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in BCRX. Paloma Partners Management Co bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth approximately $84,000. Amalgamated Bank bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth approximately $122,000. Summit Securities Group LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth approximately $132,000. Legal & General Group Plc lifted its holdings in shares of BioCryst Pharmaceuticals by 14.5% in the 4th quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock worth $156,000 after purchasing an additional 2,453 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth approximately $169,000. 91.96% of the stock is currently owned by institutional investors and hedge funds.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Further Reading: How does a reverse stock split work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.